Methods Of Treating Asthma .

Abstract: Methods for agents useful for treating asthma are disclosed. The methods include screening for agents that inhibit the producfion of a PKC-Θ protein, as well as for agents that inhibit the kinase activity of a PKC-Θ protein, or a functional fragment thereof, wherein such agents are useful for treating asthma. The methods also include screening for agents that inhibit the production of a reporter gene product encoded by a nucleic acid sequence operably linked to a PKC -Θ promoter. Also disclosed are methods of treating asthma that include administering an agent that inhibits the production of a functional PKC-Θ protein or the kinase activity of a PKC-Θ protein or a functional fragment thereof. An isolated mast cell lacking expression of endogenous PKC-Θ is also disclosed.

Patent Information

Application #

Filing Date

19 July 2006

Publication Number

20/2007

Publication Type

INA

Invention Field

CHEMICAL

Status

Email

Parent Application

Applicants

WYETH

FIVE GERALD FARMS, MADISON, NJ 07940

Inventors

1. CHAUDHARY, DIVYA

27 JENKINS ROAD, ANDIVER, MA 01810

2. KASAIAN, MARION

18 CONCORD STREET, #1, CHARLESTOWN, MA 02129,

3. WILLIAMS, CARA

11, OBSERVATORY ROAD, METHUEN, MA 01844,

4. MARUSIC, SUZANA

70 DIVIDENCE ROAD, READING, MA 01867

5. CZERWINSKI, ROBERT, M

160 OLD WESTBOARDE ROAD, NORTH GRAFTO9N, MA 01536

Specification

Methods for agents useful for treating asthma are disclosed. The methods include screening for agents that inhibit the producfion of a PKC-Θ protein, as well as for agents that inhibit the kinase activity of a PKC-Θ protein, or a functional fragment thereof, wherein such agents are useful for treating asthma. The methods also include screening for agents that inhibit the production of a reporter gene product encoded by a nucleic acid sequence operably linked to a PKC -Θ promoter. Also disclosed are methods of treating asthma that include administering an agent that inhibits the production of a functional PKC-Θ protein or the kinase activity of a PKC-Θ protein or a functional fragment thereof. An isolated mast cell lacking expression of endogenous PKC-Θ is also disclosed.

Documents

Application Documents

#	Name	Date
1	02029-kolnp-2006-form-3-1.1.pdf	2011-10-07
1	2029-KOLNP-2006-(18-03-2016)-ABANDONED-LETTER.pdf	2016-03-18
2	02029-kolnp-2006 abstract.pdf	2011-10-07
2	02029-kolnp-2006-form-18.pdf	2011-10-07
3	02029-kolnp-2006-correspondence-1.2.pdf	2011-10-07
3	02029-kolnp-2006 assignment.pdf	2011-10-07
4	02029-kolnp-2006-correspondence-1.1.pdf	2011-10-07
4	02029-kolnp-2006 claims.pdf	2011-10-07
5	02029-kolnp-2006 priority document.pdf	2011-10-07
5	02029-kolnp-2006 correspondence others.pdf	2011-10-07
6	02029-kolnp-2006 pct form.pdf	2011-10-07
6	02029-kolnp-2006 description(complete).pdf	2011-10-07
7	02029-kolnp-2006 others.pdf	2011-10-07
7	02029-kolnp-2006 drawings.pdf	2011-10-07
8	02029-kolnp-2006 international search authority report.pdf	2011-10-07
8	02029-kolnp-2006 form-1.pdf	2011-10-07
9	02029-kolnp-2006 form-3.pdf	2011-10-07
9	02029-kolnp-2006 international publication.pdf	2011-10-07
10	02029-kolnp-2006 form-5.pdf	2011-10-07
11	02029-kolnp-2006 form-3.pdf	2011-10-07
11	02029-kolnp-2006 international publication.pdf	2011-10-07
12	02029-kolnp-2006 form-1.pdf	2011-10-07
12	02029-kolnp-2006 international search authority report.pdf	2011-10-07
13	02029-kolnp-2006 drawings.pdf	2011-10-07
13	02029-kolnp-2006 others.pdf	2011-10-07
14	02029-kolnp-2006 description(complete).pdf	2011-10-07
14	02029-kolnp-2006 pct form.pdf	2011-10-07
15	02029-kolnp-2006 correspondence others.pdf	2011-10-07
15	02029-kolnp-2006 priority document.pdf	2011-10-07
16	02029-kolnp-2006 claims.pdf	2011-10-07
16	02029-kolnp-2006-correspondence-1.1.pdf	2011-10-07
17	02029-kolnp-2006 assignment.pdf	2011-10-07
17	02029-kolnp-2006-correspondence-1.2.pdf	2011-10-07
18	02029-kolnp-2006 abstract.pdf	2011-10-07
18	02029-kolnp-2006-form-18.pdf	2011-10-07
19	2029-KOLNP-2006-(18-03-2016)-ABANDONED-LETTER.pdf	2016-03-18
19	02029-kolnp-2006-form-3-1.1.pdf	2011-10-07